GlassScriptPhysician profile
Joel C Ang
NPI 1992792568
$13,767.58
in general payments reported to CMS, 2019-2025
27 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,348 · 2020: $1,536 · 2021: $2,174 · 2022: $188 · 2023: $129 · 2024: $210 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,003.92 | 2019-2025 | |
| Theratechnologies INC. | $1,513.85 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Viiv Healthcare Company | $865.19 | 2019-2024 | Dovato |
| Medicure Pharma INC. | $600.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $346.57 | 2019-2020 | |
| Janssen Biotech, INC. | $298.72 | 2019-2020 | |
| Novo Nordisk INC | $242.03 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $239.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $217.61 | 2019 | |
| Pfizer INC. | $119.21 | 2019-2020 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Allergan, INC. | $105.95 | 2019-2020 | |
| Amarin Pharma, INC. | $101.95 | 2019-2021 | |
| Lilly USA, LLC | $101.40 | 2019-2025 | Mounjaro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $99.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.70 | 2019-2020 | |
| Antares Pharma, INC. | $96.06 | 2019 | |
| Mylan Institutional INC. | $95.98 | 2019 | |
| Napo Pharmaceuticals INC | $71.05 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $65.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.12 | 2019 | |
| Janssen Scientific Affairs, LLC | $26.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $22.94 | 2019 | |
| Aytu Biopharma, INC. | $16.31 | 2019 | |
| Endo Pharmaceuticals INC. | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Ang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.